Market reports & researches
LOG IN | Services | Contact | Custom Research



Main Government and Public Sector Social Studies The Role of Self-Medication in Cost-Containment in the United States
Publications

(Currently 512486 Items)


Partners


Social Studies / REPORT INFORMATION

The Role of Self-Medication in Cost-Containment in the United States

DateApr, 2005
Pages0
Price / format$1012 / PDF E-mail From Publisher

$1 012 

Report Information | Custom-Tailored Research | Product Trade Lead


Abstract:
 The price of this report has been reduced due to its age. The original price was $1,900 for PDF E-mail From Publisher.
With sales in 2003 estimated at $17.5 billion, the U.S. market for over-the-counter (OTC) drugs is by far the largest in the world, but it is arguably far from being the most dynamic self-medication market. The U.S. market's sluggish performance is attributable in part to the very cautious attitude of the FDA toward the reclassification of prescription drugs as nonprescription medicines, a process known as "Rx-to-OTC switching." However, recent statements made by the FDA indicate that its attitude toward Rx-to-OTC switching is about to change. We begin this report by considering the perspectives on self-medication of three major stakeholder groups: consumers, payers, and manufacturers, plus the position of the FDA. We then examine the cost-containment implications of Rx-to-OTC switching in two drug classes that have had recent switch approvals (nonsedating antihistamines and proton pump inhibitors) and two classes that may see switches in the near future (statins and obesity therapies). We conclude with a brief assessment of the outlook and implications for the pharmaceutical industry.


Table of contents:
Overview
Stakeholders' Perspectives on Self-Medication
Key Drug Classes
Outlook and Implications for the Pharmaceutical Industry


Table 1. Number of Active Ingredients Available Over the Counter in Each Major Drug Class in the Leading Pharmaceutical Markets, October 2004
Table 2. Retail Prices of Select Nonsedating Antihistamines at a Leading Internet Pharmacy, March 2005
Table 3. Effect of Various Health Plan Responses to the Switch of Loratadine to OTC Status
Table 4. Retail Prices of Select Proton Pump Inhibitors at a Leading Internet Pharmacy, March 2005
Table 5. Impact of the Launch of Prilosec OTC on the Status of Proton Pump Inhibitors in the Arkansas State Employee Health Plan Formulary


Figure 1. Number of WellPoint Health Networks Plan Members Who Filled Prescriptions for Nonsedating antihistamines in the First Five Months of 2002 and 2003
Figure 2. Proton Inhibitors’ Prescription Shares Before and After the introduction of Coverage of OTC Omeprazole in the Arkansas State Employee Health Plan




Order this report

  Company name:
  Contact person:
  Phone/fax:
  Email:
  Comments:
   


Product Trade Lead
0 leads found


Add New Buy/Sell Lead

© 2007-2010 MarketReportFinder.com